Merus Aktie (A2AKFX

Was macht Merus?

Unternehmensprofil

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Chart der Merus Aktie

Charttool öffnen

Aktuelle Nachrichten zu Merus

Weitere Nachrichten

Das berichten andere über Merus

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

Merus (MRUS) delivered earnings and revenue surprises of -90.60% and -15.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for...

Merus NV stock hits all-time high, reaching 62.98 USD By Investing.com

Merus NV stock hits all-time high, reaching 62.98 USD

GNW-News: Merus hält Vorträge auf bevorstehenden Investorenkonferenzen

^UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 27, 2025 (GLOBE NEWSWIRE) Merus N.V. (https://merus.nl/) (Nasdaq: MRUS), ein Unternehmen für klinischeOnkologie, das...

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus (MRUS) delivered earnings and revenue surprises of -20.69% and 238.55%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead...